rHuEPO

DRUG7 trials

Sponsors

Amgen, University of British Columbia, Chugai Pharmaceutical, Peking Union Medical College Hospital, AstraZeneca

Conditions

AnemiaAnemia of Chronic Kidney DiseaseAnemia, Iron DeficiencyCancerEnd Stage Renal DiseaseHemodialysis PatientsNeoplasmsNon-Myeloid Malignancies

Phase 3

Anemia in Patients With a Non-Myeloid Malignancy

CompletedNCT00038064

AmgenAnemia, Neoplasms

Start: 2002-01-31End: 2004-04-30Updated: 2008-09-15

Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy

CompletedNCT00111137

AmgenCancer, Non-Myeloid Malignancies

Start: 2003-02-28End: 2004-04-30Updated: 2008-02-28

Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.

CompletedNCT00323752

University of British ColumbiaScoliosis

Start: 2004-10-31End: 2007-12-31Target: 20Updated: 2008-09-25

Clinical Study of R744 to Hemodialysis Patients

CompletedNCT00491868

Chugai PharmaceuticalHemodialysis Patients

Start: 2007-06-30End: 2008-08-31Updated: 2009-02-02

NESP Pediatric Study

CompletedNCT00527137

AmgenEnd Stage Renal Disease, Pre-dialysis

Start: 2000-08-31End: 2004-11-30Target: 120Updated: 2013-05-08

Phase 4

A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)

CompletedNCT04655027

AstraZenecaAnemia of Chronic Kidney Disease

Start: 2021-02-22End: 2021-10-12Updated: 2024-04-22

Unknown Phase

Erythropoietin And/Or Iron Sucrose For Perioperative Anemia Management In Hip and Knee Arthroplasty

Peking Union Medical College HospitalAnemia, Iron Deficiency

Start: 2019-04-24End: 2019-09-30Target: 780Updated: 2019-04-25

Related Papers

Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI).

2024-01-273 citations